Oncotarget

Clinical Research Papers:

Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma

Ying Xiong _, Li Liu, Jiajun Wang, Wei Xi, Yu Xia, Qi Bai, Yang Qu, Qilai Long, Jiejie Xu and Jianming Guo

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:25650-25659. https://doi.org/10.18632/oncotarget.12827

Metrics: PDF 2728 views  |   HTML 2003 views  |   ?  


Abstract

Ying Xiong1,*, Li Liu1,*, Jiajun Wang1,*, Wei Xi1, Yu Xia1, Qi Bai1, Yang Qu1, Qilai Long1, Jiejie Xu2 and Jianming Guo1

1 Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China;

2 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China;

* These authors have contributed equally to this work

Correspondence to:

Jiejie Xu, email:

Jianming Guo, email:

Keywords: CCL-21, metastatic renal cell carcinoma, prognostic factor, overall survival, progression-free survival

Received: September 14, 2016 Accepted: October 14, 2016 Published: October 23, 2016

Abstract

Background: Chemokine (C-C motif) ligand 21 (CCL21), a ligand of the chemokine (C-C motif) receptor 7, has recently been identified as an immuno-based anti-cancer molecule for its dendritic cells and T lymphocytes chemoattractant function. The aim of this study was to investigate prognostic values of CCL21 expression in metastatic renal cell carcinoma patients treated with targeted therapy.

Methods: This study included 111 patients with metastatic renal cell carcinoma receiving targeted therapy. CCL21 expression was analyzed by immunohistochemistry on tissue microarrays. Prognostic value of tumoral CCL21 expression and patients’ clinical outcomes were evaluated.

Results: Kaplan-Meier method showed that low CCL21 expression was associated with shorter patient overall survival and progression-free survival (overall survival, P = 0.005; progression-free survival, P = 0.044). Further stratified analysis showed that low CCL21 expression was significantly associated with shorter overall survival in clear cell renal cell carcinoma patients (P = 0.017) and patients treated with sorafenib (P = 0.009). Low CCL21 expression was also an adverse independent risk factor for overall survival (hazard ratio, 2.106; 95% CI, 1.286-3.450; P = 0.003) and progression-free survival (hazard ratio 1.617; 95%CI 1.060-2.465; P = 0.026) in multivariate analyses. CCL21 expression was significantly associated with treatment best response to targeted therapy (P = 0.009). This molecule could also be combined with Heng risk model to increase its overall survival predictive accuracy.

Conclusion: Low CCL21 expression was a potential independent adverse prognostic biomarker for overall survival and progression-free survival for metastatic renal cell carcinoma patients treated with targeted therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12827